a 34 % reduction in the incidence of definite coronary heart disease events was observed in dyslipidemic men treated with gemfibrozil in the helsinki heart study , a controlled 5-year , double-blind primary prevention trial for coronary heart disease .
C0018799
the
C0018787
heart